



Proteomics International

LABORATORIES LTD

Press Release

22 June 2018

ASX code: PIQ

Proteomics International at American Diabetes Association 78th Scientific Sessions following new license deals for diabetic kidney disease predictive test in USA and Mexico

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has just signed license agreements for its world-leading PromarkerD predictive test for diabetic kidney disease with USA and Mexico partners.

PromarkerD, a simple blood test kit that uses a unique protein 'fingerprint' to provide an early detection of the onset of diabetic kidney disease, can offer accurate testing of the more than 43 million people with diabetes in the USA and Mexico - and even people with pre-diabetes.

PromarkerD is the first test able to predict the onset of diabetic kidney disease, saving lives and billions in healthcare dollars by warning of a decline in kidney function up to four years in advance.

Proteomics International Managing Director Dr Richard Lipscombe is at the ***American Diabetes Association 78th Scientific Sessions*** (June 22-26, 2018, Orlando, Florida) to discuss PromarkerD license deals.

About the USA license agreement with PrismHealthDx, Inc. (PHDx)

- USA PromarkerD launch targets the world's biggest spending country on diabetes care
- World leading predictive test can save and extend lives by avoiding diabetic kidney disease
- Test to be offered to patients through a partnership with precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx)
- PHDx will launch the PromarkerD test nationally
- Potential to save US healthcare system billions of dollars in treatment and dialysis costs

About the Mexico license agreement with Patia Biopharma

- Diabetes is responsible for one in seven deaths in Mexico, killing more people than cancer
- Mexico has one of the highest rates of diabetes in the world, with 13 million adults suffering from the condition
- Through Patia's network the test will initially be introduced to private hospitals and private clinics, and then expanded into government hospitals and Carlos Slim Foundation programs.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Dialysis treatment alone costs US\$72,000 per person per year, according to the US Renal Data System. Diabetes accounts for 44 per cent of chronic kidney disease cases in the USA.

Dr Lipscombe said PromarkerD was a major weapon in the battle against the diabetes epidemic. “Regular testing and early diagnosis of diabetic kidney disease with PromarkerD can help millions of people avoid costly and invasive dialysis treatment or a kidney transplant,” he said.

For every million people living with diabetes, 10 per cent—or 100,000 people—are expected to suffer a rapid decline in kidney function within the next four years.

The PromarkerD test is able to predict this decline in kidney function in 86 per cent of cases.

This means that for example if every one of the 30 million Americans with diabetes took the test it would potentially identify 2.6 million of the 3 million people on the path to kidney disease. Those identified would require systematic re-testing to verify effectiveness of treatments. Another 84 million American adults—more than 1 out of 3—have prediabetes, a precursor to diabetes, and may also benefit from taking the PromarkerD test.

Dr Lipscombe said the breakthrough deal for PromarkerD in the USA and Mexico is important because it paves the way for other licensing contracts. “It is great to see PromarkerD launching in the world's largest healthcare market as we further negotiations to commercialise the test in other countries including Japan, Australia, China and Europe.”

ENDS

About PromarkerD (www.PromarkerD.com)

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

Further information is available through the PromarkerD web portal.

About PHDx, Inc (www.phdxinc.com)

PrismHealthDx, Inc. (PHDx) is a precision medicine diagnostic laboratory and services company specialising in comprehensive biomarker testing to detect the onset of disease and serious medical conditions at their earliest and most treatable stage. PHDx provides a ‘one-stop-shop’ opportunity to integrate best-in-class laboratory and clinical medicine into practices, driving better clinical outcomes and helping to make an immediate difference in the lives of their patients. PHDx's management team has extensive experience in developing and commercialising novel assays and they are committed to advancing new diagnostic and disease management capabilities. PHDx works in partnership with academic leaders, industry leaders, and clinical providers.

About Patia Biopharma (www.patiadiabetes.com)

Patia Biopharma is a Mexican company focused on promoting personalised preventive medicine across Mexico, Latin America and worldwide. Patia offers the medical community a vast array of genomic, metabolomic and proteomic tests for risk assessment and early diagnosis, which support early interventions in patients with diabetes.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

For further information please contact:

Chuck Morrison
Head of Business Development
Proteomics International
E: c.morrison@proteomicsinternational.com
T: +1 617 331 2975
www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
E: team@dmgpr.com
T: USA 415 951 3228
T: AU 02 8218 2144